Adverse pregnancy and neonatal outcomes associated with Neisseria gonorrhoeae, Mycoplasma genitalium, M. hominis, Ureaplasma urealyticum and U. parvum: a systematic review and meta-analysis protocol. by Vallely, Lisa M et al.
1Vallely LM, et al. BMJ Open 2018;8:e024175. doi:10.1136/bmjopen-2018-024175
Open access 
Adverse pregnancy and neonatal 
outcomes associated with Neisseria 
gonorrhoeae, Mycoplasma genitalium, 
M. hominis, Ureaplasma urealyticum 
and U. parvum: a systematic review and 
meta-analysis protocol
Lisa M Vallely,1 Dianne Egli-Gany,2 William Pomat,3 Caroline SE Homer,4,5 
Rebecca Guy,6 Handan Wand,7 Bronwyn Silver,8 Alice R Rumbold,9 
John M Kaldor,1 Nicola Low,2 Andrew J Vallely1,10
To cite: Vallely LM, Egli-
Gany D, Pomat W, et al.  
Adverse pregnancy and 
neonatal outcomes associated 
with Neisseria gonorrhoeae, 
Mycoplasma genitalium, 
M. hominis, Ureaplasma 
urealyticum and U. parvum: a 
systematic review and meta-
analysis protocol. BMJ Open 
2018;8:e024175. doi:10.1136/
bmjopen-2018-024175
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
024175).
LMV and DE-G contributed 
equally.
Received 14 May 2018
Revised 24 August 2018
Accepted 10 October 2018
For numbered affiliations see 
end of article.
Correspondence to
Dr Lisa M Vallely;  
 lvallely@ kirby. unsw. edu. au
Protocol
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Several bacterial sexually transmitted 
and genital mycoplasma infections during pregnancy 
have been associated with poor pregnancy and perinatal 
outcomes. Comprehensive and systematic information 
about associations between sexually transmitted infections 
(STI) and genital infections in pregnancy and adverse 
perinatal outcomes is needed to improve understanding 
about the evidence for causal associations between 
these infections and adverse pregnancy and neonatal 
outcomes. Our primary objective is to systematically 
review the literature about associations between: (1) 
Neisseria gonorrhoeae in pregnancy and preterm birth; (2) 
Mycoplasma genitalium in pregnancy and preterm birth; 
(3) M. hominis, Ureaplasma urealyticum and/or U. parvum 
in pregnancy and preterm birth.
Methods and analysis We will undertake a systematic 
search of Medline, Excerpta Medica database and the 
Cochrane Library and Cumulative Index to Nursing and 
Allied Health Literature. Following an initial screening of 
titles by one reviewer, abstracts will be independently 
assessed by two reviewers before screening of full-text 
articles. To exclude a manuscript, both reviewers need to 
agree on the decision. Any discrepancies will be resolved 
by discussion, or the adjudication of a third reviewer. 
Studies will be included if they report testing for one 
or more of N. gonorrhoeae, M. genitalium, M. hominis, 
U. urealyticum and/or U. parvum during pregnancy and 
report pregnancy and/or birth outcomes. In this review, the 
primary outcome is preterm birth. Secondary outcomes 
are premature rupture of membranes, low birth weight, 
spontaneous abortion, stillbirth, neonatal mortality and 
ophthalmia neonatorum. We will use standard definitions, 
or definitions reported by study authors. We will examine 
associations between exposure and outcome in forest 
plots, using the I2 statistic to examine between study 
heterogeneity. Where appropriate, we will use meta-
analysis to combine results of individual studies.
Ethics and dissemination This systematic review of 
published literature does not require ethical committee 
approval. Results of this review will be published in a peer 
reviewed, open access journal.
PrOsPErO registration number CRD42016050962.
IntrOduCtIOn  
Several bacterial sexually transmitted infec-
tions (STI) during pregnancy have been 
reported to be associated with poor preg-
nancy outcomes.1–3 Chlamydia trachomatis 
(CT, chlamydia), Neisseria gonorrhoeae (NG), 
Trichomonas vaginalis (TV, trichomoniasis) 
and Mycoplasma genitalium (MG) have all 
been associated with one or more of the 
following: premature rupture of membranes 
strengths and limitations of this study
 ► This systematic review is, as far as we are aware, 
the first to address associations between adverse 
pregnancy and neonatal outcomes and the sexually 
transmitted pathogens Neisseria gonorrhoeae and 
Mycoplasma genitalium, and associations with other 
genital mycoplasmas.
 ► The systematic review, which covers more than one 
infection, will be efficient because these infections 
are often tested for and reported in the same study.
 ► This review will appraise the quality of each study 
according to the study design (ie, cross-sectional, 
case–control, cohort or clinical trial).
 ► The results of this review can be used to estimate 
the burden of disease due to these sexually trans-
mitted and genital infections.
 ► A limitation of this review is that we will only be able 
to examine associations separately for Ureaplasma 
urealyticum and U. parvum in more recent studies 
because older studies did not distinguish between 
the two species.  on
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(PROM), preterm birth and low birth weight (LBW)1–10; 
CT and NG are also recognised as causes of neonatal 
conjunctivitis and CT is a cause of neonatal pneumonia.11 
Other genital mycoplasmas in the reproductive tract 
are M. hominis, Ureaplasma urealyticum and U. parvum. 
Combined testing for these organisms is common and 
they are very frequently found in the vagina.12 Routine 
testing and treatment of asymptomatic non-pregnant 
women are discouraged because the evidence that they 
cause disease is questionable.13 Detection of these organ-
isms during pregnancy has been reported in some studies, 
however, to be associated with spontaneous abortion, 
stillbirth, preterm birth, LBW and perinatal morbidity 
and mortality.13–15 In a large cohort study in south Asia, 
Ureaplasma spp (U. urealyticum and U. parvum together) 
were the second most common organism identified in 
infants with signs of serious bacterial infection than from 
healthy babies and were more commonly isolated from 
sick than healthy infants.16 Bacterial culture for U. urea-
lyticum does not distinguish between two closely related 
species, U. urealyticum and U. parvum and associations 
with each of these subspecies and adverse pregnancy 
outcomes are not consistent.17 18
Comprehensive and systematic information about asso-
ciations between STI, other genital infections in preg-
nancy and adverse pregnancy and perinatal outcomes 
is needed to improve understanding about the evidence 
for causal associations, to contribute to estimates of the 
global burden of STI and to determine the potential 
impact of preventive interventions. For example, associ-
ations between syphilis in pregnancy and preterm birth, 
LBW, stillbirth and systemic congenital infection are 
well-established, the burden of disease has been estimated 
and a global strategy for elimination of congenital syph-
ilis is in place.19–21 For other STI and reproductive tract 
infections, the consistency and causal nature of associa-
tions are not as clear. Much of the published work on STI, 
reproductive tract infections and their association with 
adverse birth outcomes comes from middle-income and 
high-income countries, with less evidence from low-in-
come settings which have the highest prevalence rates of 
STI in pregnancy.1 22
Systematic reviews that synthesise findings from 
different studies can help to examine the consistency 
and risk of bias of the body of evidence. To date, system-
atic reviews about adverse pregnancy outcomes have 
examined associations with CT,23 TV24 and MG.25 For 
CT, there are published and ongoing reviews. Silva et 
al23 reported on 12 studies published up to January 2010 
and found that CT infection during pregnancy was asso-
ciated with an increased risk of preterm labour, LBW 
and perinatal mortality. A protocol in the online data-
base PROSPERO shows that another systematic review 
about CT and adverse pregnancy outcomes is ongoing.26 
For TV, a systematic review by Silver et al24 included 11 
studies published up to May 2013 and found that ante-
natal TV infection was associated with increased risk 
of preterm birth, PROM and small for gestational age 
infants. For MG, a systematic review by Lis et al25 included 
nine studies published up to June 2014 and found that 
MG was associated with preterm birth and spontaneous 
abortion. Nucleic acid amplification tests (NAATs) for 
MG are only now becoming widely available, so a new 
systematic review of evidence about MG is warranted.25 
For NG and adverse pregnancy and neonatal outcomes 
we are unaware of any systematic reviews. Multiplex 
NAATs now include targets for M. hominis, U. urealyticum 
and U. parvum. We are unaware of a systematic review 
that has synthesised quantitative data about associations 
between these genital mycoplasmas and adverse preg-
nancy outcomes. M. hominis, in particular, is strongly 
associated with bacterial vaginosis (BV) which itself is 
strongly associated with adverse pregnancy outcomes.15 
The use of antibiotic therapy for treating BV in preg-
nancy has been found to eradicate BV during pregnancy 
but did not reduce the risk of preterm birth, or preterm, 
prelabour rupture of membranes.27 It would be useful 
to examine whether or not co-existing BV modifies any 
association between genital mycoplasmas and adverse 
pregnancy outcomes. STIs and genital mycoplasmas can 
co-occur and the use of multiplex NAATs means that find-
ings about multiple organisms are increasingly presented 
together.13 28 A single search strategy that includes terms 
for different pathogens and outcomes could make the 
work of a systematic review more efficient.
Objectives
The overall aim of this systematic review is to examine 
associations between selected infections in pregnancy 
and adverse pregnancy and/or neonatal outcomes. We 
have the following specific objectives:
1. To determine whether NG infection during pregnancy 
increases the risk of preterm birth.
2. To determine whether MG infection during pregnancy 
increases the risk of preterm birth.
3. To determine whether infection with the genital tract 
infections M. hominis, U. urealyticum and U. parvum 
during pregnancy increase the risk of preterm birth.
4. To examine associations between each of the named 
infections during pregnancy and other adverse preg-
nancy or neonatal outcomes: LBW, PROM, spon-
taneous abortion; perinatal mortality; ophthalmia 
neonatorum.
MEthOds And AnAlysIs
We wrote the systematic review protocol in accordance 
with the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses Protocols guidelines29 (online supple-
mentary file 1), adapting it where necessary to our review 
of observational research studies. If we need to amend 
the protocol, we will update the PROSPERO record with 
the date of each amendment, accompanied by a descrip-
tion of the change and the rationale.
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Eligibility criteria
Studies will be selected if they report one or more preg-
nancy, perinatal or neonatal outcome in women with NG, 
MG, M. hominis, U. urealyticum and/or U. parvum.
study design
We will include any study design with data that allows 
comparison between women with and without one of the 
included infections. Eligible study designs include case–
control, cross-sectional, cohort studies and clinical trials. 
Individual case reports, case series without a control 
group and opinion articles will not be included.
Participants
Women who have been tested during pregnancy for NG, 
MG, M. hominis, U. urealyticum or U. parvum using a labo-
ratory diagnostic test, for example culture or NAAT, and 
for whom pregnancy and/or neonatal health outcomes 
are reported.
Infections
For studies that report more than one of the eligible infec-
tions, we will only include studies for which we can extract 
data separately for each infection, with the exception of 
U. urealyticum. We will assume that studies reporting on U. 
urealyticum alone have not differentiated between U. urea-
lyticum and U. parvum. We assume that studies published 
after 2000 and reporting separate results for U. urealyt-
icum and U. parvum have conducted tests that distinguish 
between these organisms.
Exposures or interventions
For observational study designs, the exposures of interest 
are: (1) NG; (2) MG; (3) M. hominis, U. urealyticum and/
or U. parvum infection, diagnosed using a recognised 
laboratory test. For intervention studies, the intervention 
of interest is antibiotic treatment for a detected NG, MG, 
other genital mycoplasma infection or antibiotic prophy-
laxis. The comparator is women who did not receive anti-
biotic treatment for NG, MG or other genital mycoplasma 
infection.
Exclusion criteria
Individual case reports, case series, opinion articles and 
studies without a control group will be excluded.
Studies including only mycoplasma infections without 
differentiating between specific mycoplasmas and arti-
cles that pool different STI and mycoplasma infections 
together will be excluded.
Information sources
We will search Medline, Excerpta Medica database and 
the Cochrane Library and Cumulative Index to Nursing 
and Allied Health Literature to identify relevant studies 
in humans only. We will not apply language or date limits 
to the search, but will only include articles published in 
English or German.
search strategy
The search strategy includes Medical Subject Headings 
(MeSH) and keywords related to pregnancy, infections 
(NG, MG, M. hominis, U. urealyticum and/or U. parvum) 
and pregnancy, birth and neonatal outcomes (table 1). 
The ‘explode’ function will be applied to each MeSH 
heading.
We will search each database from its earliest date, 
including online publication. To identify additional rele-
vant studies, we will search the reference lists of included 
studies or relevant reviews identified during the search. 
LV, the lead author of this manuscript, who is also the lead 
person for this planned review, will conduct the search.
study rECOrds
data management
Search results will be imported into an Endnote (Clarivate 
Analytics 2017, Boston) library and all duplicates will be 
removed. We will use REDCap (Research Electronic Data 
Capture, Vanderbilt University, TN), a secure web appli-
cation for building and managing online databases for 
screening and data extraction. DEG will design and pilot 
the forms for screening and data extraction. All extracted 
Table 1 Search strategy
1. Terms for population ‘pregnancy’ or ‘prenatal’ or ‘antenatal’
2. Terms for exposure ‘Neisseria gonorrhoeae’ or ‘gonorrhea’ or ‘gonorrhoea’;
‘Mycoplasma genitalium’; ‘Mycoplasma hominis’;
‘Ureaplasma urealyticum’; ‘Ureaplasma parvum’
3. Terms for outcomes ‘birth outcome’ or ‘adverse birth outcome’ or ‘adverse pregnancy outcome’ or ‘perinatal morbidity’ or 
‘perinatal mortality’ or ‘perinatal outcome’ or ‘premature birth’ or ‘premature delivery’ or ‘very preterm 
birth’ or ‘preterm birth’ or ‘preterm delivery’ or ‘premature labour’ or ‘preterm labour’ or ‘premature 
labor’ or ‘preterm labor’ or ‘premature rupture of membranes’ or ‘preterm rupture of membranes’ or 
‘preterm premature rupture of membranes’ or ‘low birth weight’ or ‘intrauterine growth retardation’ 
or ‘intrauterine growth restriction’ or ‘small for gestational age’ or ‘gestational age’ or ‘stillbirth’ or 
‘perinatal mortality’ or ‘perinatal morbidity’ or ‘perinatal death’ or ‘neonatal mortality’ or ‘neonatal 
morbidity’ or ‘neonatal death’ or ‘fetal death’ or ‘miscarriage’ or ‘spontaneous abortion’ or ‘ophthalmia 
neonatorum’ or ‘chorioamnionitis’
4.Search = #1 + # 2 + # 3
Free text terms in the search strategy will use truncated and wildcard forms, for example, pregn*, gono*.
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data will be imported into Stata V.14.0 (StataCorp LLC, 
TX) for analysis.
selection process
We will conduct screening for inclusion in three stages:
1. One reviewer (LV) will review each title and decide on 
records that can be excluded immediately using select-
ed criteria (online supplementary material 2). All oth-
er records advance to the next stage.
2. In the second stage, two reviewers (LV, DE-G) will in-
dependently screen all titles and abstracts against the 
eligibility criteria. To exclude a record, both reviewers 
need to agree on the decision. Any record excluded by 
a single reviewer is checked by the second reviewer and 
discrepancies will be resolved by discussion, or by the 
adjudication of a third reviewer.
3. In the third stage, two reviewers (LV, DE-G) will screen 
the full text of each record independently against 
the eligibility criteria. To exclude a manuscript, both 
reviewers need to agree on the decision. Any manu-
script excluded by a single reviewer is checked by the 
second reviewer and discrepancies will be resolved by 
discussion, or by the adjudication of a third reviewer. 
Reasons for exclusion of any study at stage three will 
be recorded.
data collection process
Two reviewers will extract data independently. The 
reviewers will compare their findings and resolve discrep-
ancies through discussion, or by asking a third reviewer 
to adjudicate. Where necessary we will contact the 
authors of selected manuscripts for missing or additional 
information.
data items
Table 2 outlines data items that will be extracted, including 
study characteristics, participant characteristics, presence 
or absence of infection and pregnancy and neonatal 
outcomes.
OutCOMEs
There are several potential adverse outcomes of preg-
nancy, and perinatal or neonatal outcomes. In this review 
we will use standard and recommended definitions 30 or, 
if these are not consistently defined, use the  case defin-
tions reported by the authors.  The following outcomes 
will be considered:
Primary outcome
 ► Preterm birth, defined as birth before 37 completed 
weeks’ gestation (including extremely preterm, very 
preterm and moderate to late preterm).30
Secondary outcomes
 ► PROM, including preterm (before 37 completed 
weeks gestation) rupture of membranes.
 ► LBW, defined as birth weight less than 2500 g.31
 ► Spontaneous abortion (miscarriage) (or as defined by 
study).
 ► Perinatal mortality
 – Stillbirth/fetal death in utero at more than 20 
weeks gestation (or as defined by study).
 – Neonatal mortality (death in the first 28 days of 
life).
 ► Ophthalmia neonatorum.
risk of bias in individual studies
Two reviewers will assess the methodological quality and 
risk of bias of each study included in the review inde-
pendently, using study specific checklists published by 
the UK National Institute for Health and Care Excel-
lence.32 33 The checklists enable the reviewer to appraise 
the internal and external validity of a study after consid-
ering key aspects relating to study design, including 
Table 2 Data items to be extracted
Study characteristics Population characteristics
NG, MG, MH, UU, UP 
characteristics Birth outcomes
 ► Authors.
 ► Year of study.
 ► Location and setting.
 ► Study design.
 ► Inclusion criteria.
 ► Sample size.
 ► Number of participants.
 ► Maternal age.
 ► Smoking.
 ► Ethnic group.
 ► Multiple pregnancy.
 ► Co-infection for example, 
HIV or other genital 
infection.
 ► Measure of gestational age 
(US, FH, LMP).
 ► Antibiotic treatment.
 ► Gestation at treatment.
 ► Number and/or % of 
women with NG, MG, MH, 
UU, UP.
 ► Number and/or % of 
women with one or more of 
NG, MG, MH, UU, UP.
 ► Laboratory test (type).
 ► Specimen type (urine, 
vaginal swab, endocervical 
swab, etc).
 ► Specimen collection method 
(self/clinician collected).
 ► Gestation at specimen 
collection.
 ► Presence of BV.
 ► Premature rupture of 
membranes.
 ► Preterm birth.
 ► Low birth weight (<2500 g).
 ► Spontaneous abortion (less 
than 20 weeks gestation).
 ► Stillbirth/fetal death in 
utero more than 20 weeks 
gestation.
 ► Neonatal death (within first 
28 days).
 ► Ophthalmia neonatorum.
BV, bacterial vaginosis; FH, fundal height; LMP, last menstrual period; MG, Mycoplasma genitalium; MH, Mycoplasma hominis; NG, Neisseria 
gonorrhoeae; UP, Ureaplasma parvum; US, ultrasound; UU, Ureaplasma urealyticum.
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population characteristics; definition of exposure vari-
ables; outcomes assessed and methods of analyses. 
Based on these four aspects, an overall assessment of the 
internal and external validity of each study will be consid-
ered. Where the two reviewers disagree, a third reviewer 
will adjudicate.
data synthesis and analysis
We will conduct separate data synthesis and analysis, first 
for the STI NG and MG and then for the other genital 
mycoplasma infections M. hominis, U. urealyticum and 
U. parvum. The stepwise approach will make our review 
process more efficient. We will apply the same procedures 
for each group of infections.
We will develop a table summarising the key charac-
teristics of each included study, including author, study 
year, setting, study design, number of participants and 
outcomes.
For cross-sectional studies, cohort studies and clinical 
trials, the measure of association will usually be the risk ratio 
(RR, with 95% CI) and for case–control studies the measure 
of association will usually be the OR (with 95% CI). We will 
use the measure of association and 95% CI presented by 
the authors and we will check the calculation of the point 
estimate, where possible, with raw data extracted from the 
article. Study authors might also report effect estimates that 
control for potential confounding factors. Where adjusted 
estimates of effect obtained from multivariable regression 
analyses are reported, we will extract the estimate (with 
95% CI) and will record the variables included in the multi-
variable model. We have prespecified three variables that are 
likely to cause confounding, resulting in an overestimation 
of the association between the infection of interest and preg-
nancy and perinatal outcomes. We will record whether each 
of the following variables is included in multivariable anal-
yses: younger age, lower socioeconomic position and pres-
ence of other STI or reproductive tract infections.
We will display associations first in forest plots to show 
the measure of association for each exposure-outcome 
pair, stratified by study design. We will use the I2 test to 
estimate the proportion of variability in point estimates 
that can be attributed to between study heterogeneity for 
reasons other than chance.34 As a guide, we will consider 
I2 values <50% as evidence of low heterogeneity, 50%–75% 
as moderate heterogeneity and >75% as severe hetero-
geneity. We will investigate reasons for heterogeneity by 
stratification or, where there are enough studies, meta-re-
gression. We will conduct sensitivity analyses to determine 
any effect of the following characteristics on the results: 
standard versus author-defined outcome definitions; low 
versus high risk of bias. We will conduct subgroup analyses 
to investigate the following possible sources of heteroge-
neity: country or region of study; diagnostic test (NAAT, 
culture, other); trimester of pregnancy when infection 
was detected (first, second, third); decade of study (pre-
1980, 1980–1989, 1990–1999, 2000 or later); presence or 
absence of BV.
Where appropriate, for outcomes reported by two or 
more studies of the same design, we will use meta-analysis 
to estimate a summary RR (95% CI) or OR (95% CI). If 
heterogeneity is moderate or severe, we will use a random 
effects model.35 The random effects model estimates the 
average effect across all studies and assumes that the true 
strength of association differs between studies. If hetero-
geneity is absent or low, we will use a fixed effects model. 
The fixed effects model assumes that the effect is similar 
across all studies and that variation between studies is 
due only to chance. We will conduct separate analyses for 
studies that record the presence of exposure before the 
outcome and studies in which exposure and outcome are 
measured at the same time.
We will examine the results of adjusted analyses using 
the same approach as for unadjusted estimates.
All data will be analysed using Stata V.14.0 (StataCorp 
LLC, TX).
Meta-biases
If there are more than 10 studies examining an expo-
sure-outcome association, we will look for evidence of 
publication bias using funnel plots. We will examine these 
visually for evidence of asymmetry and use the Begg and 
Mazumdar rank correlation test for asymmetry.36
 We have not planned to look for evidence of selective 
reporting within studies.
Confidence in cumulative evidence
We will use the Grading of Research Evidence Assess-
ment and Development approach to assess the body of 
evidence, considering the observational study designs,37 
and provide a descriptive assessment of certainty in the 
cumulative evidence.
Patient and public involvement
Patients and/or the public were not involved in the devel-
opment of this review protocol. We will publish the find-
ings in open access publications which are available for 
the public to read and make use of the data.
dIsCussIOn
This systematic review will fill gaps in knowledge about 
potential associations between STI and reproductive 
tract infections, and adverse pregnancy and perinatal 
outcomes. Our systematic review will address infections 
that have not previously been assessed in a systematic 
review (NG) and some genital mycoplasmas.
The association between STI and other genital infec-
tions, and adverse pregnancy and perinatal outcomes has 
been documented from a number of high- and middle-in-
come settings.2 5 8 We will search multiple information 
sources and expect to find additional studies conducted 
in less well-resourced settings. Additional steps to mini-
mise bias include independent assessments by two 
reviewers to reduce bias in the selection of studies and 
extraction of data and consideration of adjusted effect 
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sizes and specific prespecified confounding factors in 
the analysis. However, we also anticipate some challenges 
that are specific to our review. First, we are reviewing the 
association between U. urealyticum and adverse pregnancy 
outcomes. U. urealyticum is now recognised to comprise 
two species, U. urealyticum and U. parvum. We will only be 
able to examine associations for these separate species 
in more recent studies, reducing the number of studies 
available for analysis. Second, we might not be able to 
determine whether trimester of pregnancy in which 
infection occurs results in different outcomes. Infections 
diagnosed in the third trimester might have been present 
throughout. Conversely, infections diagnosed early in 
pregnancy might already have been treated. We will take 
these factors into account when interpreting the findings.
Studies that synthesise information about complications 
of STI and reproductive tract infections can be used in 
the estimation of the burden of disease. Until now, global 
burden of disease estimates of the burden of disease due 
to bacterial STI other than syphilis only include disability 
resulting from pelvic inflammatory disease and infer-
tility. Ultimately, the findings of this review could help to 
improve decisions about both the prevention and clinical 
management of NG and genital mycoplasma infections 
in pregnancy.
Ethics and dissemination
We will present our results at an international medical 
conference that focuses on the prevention and treatment 
of STI. We will publish the results of this review in a peer 
reviewed, open access medical journal.
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